In experimental diabetic cardiomyopathy complicated with abdominal aortic coartaction, implementation of LKSL, a peptide that antagonizes TSP1-dependent TGF-β activation, had beneficial actions on the myocardium by inhibiting TGF-β-driven fibrosis [52]. Here, TGFB1 is linked to diabetic cardiomyopathy.